Multimodal Clinical Mass Spectrometry to Target Treatment Resistance


Targeting Treatment Resistance

Precision medicine aims at offering each patient an individualized treatment based on a deep analysis of the biological characteristics of the patient and the disease. The MSTARS research core in Berlin fosters precision medicine by establishing a mass spectrometry based platform in the clinics that allows standardized and high throughput analysis of patient material to support therapy recommendations. The disease foci of MSTARS are different cancer entities (e.g. head and neck squamous cell carcinoma, leukemia, ovarian cancer, neuroblastoma, prostate cancer) and inflammatory diseases (e.g. myocarditis, chronic liver diseases).
The consortium analyzes biosamples by mass spectrometry or mass spectrometry-coupled imaging based technologies to characterize the proteome and metabolome. Bioinformaticians integrate the acquired data and include already existing omics data, such as genomics and transcriptomics, striving for the identification of biomarkers and signatures for therapy resistances. The acquired knowledge is directly brought back into the clinics supporting future clinical study design and therapeutic decisions.

Contact us

Do you have any questions? We are looking forward to your message.

Send us a message

Charité - Universitätsmedizin Berlin

Charité Comprehensive Cancer Center
Charitéplatz 1
10117 Berlin

Young Expansion of the MSTARS Consortium

MSTARS strengthened and expanded its areas of “visual proteomics” and “method development for quantitative proteomics” by recruiting two young investigator groups.
Read article